Loading...
Market
How will competitors respond to Roche's successful Phase I obesity drug trials by mid-2025?
4
Resolution / Starting Odds
Novo Nordisk launches competitive drug • 30%
Pfizer accelerates similar drug development • 30%
No significant competitor response • 40%
Press releases or official statements from the companies
Story
Roche's Obesity Drug Shows Positive Phase I Results, Shares Rise 4.7% After 18.8% Weight Loss
May 16, 2024, 09:25 AM
Roche has reported positive Phase I results for its experimental obesity drug, developed by newly acquired Carmot Therapeutics. The trial showed an average weight loss of approximately 18.8%, leading to a 4.7% increase in Roche shares at the market open on Thursday. The company described the results as 'encouraging' amidst growing competition in the obesity drug market. This marks the first clinical readout since Roche acquired Carmot Therapeutics for $2.7 billion.
View original story
Similar markets
Yes • 50%
No • 50%
Launch of similar drug • 33%
Acquisition or partnership announcements • 33%
No significant response • 34%
Launch new competing drug • 33%
Enhance marketing of existing drugs • 33%
No significant response • 34%
Outperforms • 25%
Underperforms • 25%
Matches • 25%
Data Inconclusive • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
No competitors • 25%
1 competitor • 25%
2 competitors • 25%
3 or more competitors • 25%
No competitors respond • 25%
1-2 competitors respond • 25%
3-5 competitors respond • 25%
More than 5 competitors respond • 25%